New transplant prep could boost survival for blood cancer patients
NCT ID NCT07025824
Summary
This study aims to find out which of two chemotherapy drugs works better to prepare patients for a stem cell transplant for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). It will compare treosulfan and melphalan in 220 adult patients who are at higher risk for side effects from standard high-dose treatment. The main goal is to see which drug leads to better overall survival and fewer complications like graft-versus-host disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML (ACUTE MYELOID LEUKEMIA) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Medizinische Fakultät der TU Dresden, Medizinische Klinik und Poliklinik I
Dresden, Germany
Contact
-
Universitätsklinikum Münster, Medizinische Klinik A, KMT-Zentrum
Münster, Germany
Contact
-
Universitätsklinikum Schleswig-Holstein, Campus Kiel
Kiel, Germany
Contact
-
Universitätsmedizin Halle (Saale)
Halle, Germany
Contact
Conditions
Explore the condition pages connected to this study.